
zzso an zzso zzso oral agent that is commonly used in the zzso treatment for type 2 diabetes, has become the focus of intense research as a potential zzso zzso This research reflects a convergence of zzso clinical, and zzso evidence, suggesting that zzso may lower cancer risk in diabetics and improve outcomes of many common zzso zzso zzso mediates an approximately 30 % reduction in the lifetime risk of cancer in diabetic zzso There is growing recognition that zzso may act zzso directly on cancer cells, primarily by zzso zzso zzso leading to the zzso of the zzso protein zzso zzso which controls energy zzso in cells, but also through other mechanisms or zzso indirectly on the host zzso largely through zzso reduction in zzso zzso leading to reduced circulating insulin levels and decreased zzso zzso zzso of the zzso zzso Support for this comes from the observation that zzso zzso cancer cell growth in zzso and delays the onset of tobacco zzso lung cancer in mice and that zzso and its analog zzso delay spontaneous tumor development zzso transgenic zzso The potential for both direct zzso effects and indirect zzso effects has sparked enormous interest, but has led to added challenges in translating zzso findings to the clinical zzso Nonetheless, the zzso of evidence has been sufficient to justify initiation of clinical trials of zzso as an zzso agent in the clinical setting, including a large-scale zzso study in breast cancer, with additional studies zzso 

